1. Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update," (in eng);Prieto-Peña;Pol Arch Intern Med,2021
2. Risk of reactivation of hepatitis B Virus (HBV) and tuberculosis (TB) and complications of Hepatitis C Virus (HCV) following tocilizumab therapy: a systematic review to inform risk assessment in the COVID-19 era;Campbell;Front Med,2021
3. Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections," (in eng);Beenhouwer;J Rheumatol,2004
4. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review," (in eng);Tracey;Pharm Ther,2008
5. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks," (in eng);Wallis;Lancet Infect Dis,2008